ANNUAL MEETING OF SHAREHOLDERS

Kevin A. Lobo

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Special Guests

FORWARD LOOKING STATEMENT

This presentation may contain information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Call to Order

BOARD OF DIRECTORS

Back Row:
RONDA E. STRYKER
ALLAN C. GOLSTON
WILLIAM U. PARFET
ANDREW K. SILVERNAIL
SRIKANT M. DATAR, PH.D

Front Row:
HOWARD E. COX, JR.
KEVIN A. LOBO
ROCH DOLIVEUX, D.V.M.
LOUISE L. FRANCESCONI

Stryker Leadership Team

STRYKER LEADERSHIP TEAM

Front Row:
RAMESH SUBRAHMANIAN, Group President, International
KEVIN A. LOBO, Chairman and Chief Executive Officer
YIN C. BECKER, VP, Communications, Public Affairs & Strategic Marketing

Middle Row:
BIJOY S.N. SAGAR, VP, Chief Information Officer
KATHERINE A. OWEN, VP, Strategy and Investor Relations
MICHAEL D. HUTCHINSON, General Counsel
LONNY J. CARPENTER, Group President, Global Quality and Operations, and European Business Operations

Back Row:
DAVID K. FLOYD, Group President, Orthopaedics
TIMOTHY J. SCANNELL, Group President, MedSurg and Neurotechnology
WILLIAM R. JELLISON, VP and Chief Financial Officer
STEVEN P. BENSCOTER, VP, Global Human Resources

stryker®

OTHER CORPORATE OFFICERS

DEAN H. BERGY, Vice President, Corporate Secretary

WILLIAM E. BERRY, JR., Vice President, Corporate Controller

JEANNE M. BLONDIA, Vice President, Finance and Treasurer

IRENE B. CORBE, Vice President, Internal Audit

DAVID G. FURGASON, Vice President, Tax

ELIZABETH A. STAUB, Vice President, Regulatory Affairs and Quality Assurance

BRONWEN R. TAYLOR, Vice President, Compliance and Risk Management

DIVISION PRESIDENTS

BUSINESSES

WAYNE D. DAHLBERG, Performance Solutions

WILLIAM J. HUFFNAGLE, Reconstructive

VIVIAN MASSON, Trauma & Extremities

BRADLEY W. PADDOCK, Spine

MARK H. PAUL, Neurovascular

J. ANDREW PIERCE, Endoscopy

BRADFORD L. SAAR, Medical

SPENCER S. STILES, Instruments

BRIAN J. WHITE, Sustainability Solutions

REGIONS

MAURICE BEN-MAYOR, South Pacific

XAVIER BERLING, Europe

LAURENCE F. I. HIPKIN, Eastern Europe, Middle East, Africa

GRAHAM A. McLEAN, Japan

DAVID A. MURPHY, Canada

M. BRENT SCOTT, Asia

stryker®

CORPORATE COUNSEL & INDEPENDENT ACCOUNTANT

CORPORATE COUNSEL

Richard C. Witzel

Partner of Skadden, Arps, Slate, Meagher & Flom LLP

INDEPENDENT ACCOUNTANT

William P. Miller

Partner of Ernst & Young LLP

Voting on Proposals

Business Update

stryker®

MISSION

**TOGETHER WITH OUR CUSTOMERS,
WE ARE DRIVEN
TO MAKE HEALTHCARE BETTER.**

VALUES

INTEGRITY

We do what's right

ACCOUNTABILITY

We do what we say

PEOPLE

We grow talent

PERFORMANCE

We deliver

stryker®

GLOBAL MEDTECH LEADER

- Pursuing global market leadership in three segments
- Growing through business unit specialization



stryker®

HISTORY OF PERFORMANCE



stryker®

GROWTH AT THE HIGH-END OF MEDTECH



* Removes the impact of changes in foreign currency exchange rates, divestitures (not applicable to Stryker) and the first twelve months of acquisition sales that affect the comparability and trend of sales

** Based on Company research of 20 representative MedTech companies

KEY GROWTH DRIVERS…

- Drive market adoption of robotic-arm assisted surgery

Mako Total Hip Arthroplasty (THA)

Mako Partial Knee Arthroplasty (PKA)

stryker

KEY GROWTH DRIVERS…

- Expand portfolio and selling teams in high growth segments
  - Extremities, Neurotechnology, Sports Medicine

ReUnion Shoulder Platform



Trevo XP ProVue Retriever

Pivot Hip Arthroscopy

stryker®

KEY GROWTH DRIVERS…

- Accelerate growth in Europe and expand Trauson outside of China

European Headquarters in Amsterdam

Trauson Manufacturing

KEY GROWTH DRIVERS

- Ramp up growth of recent acquisitions

Patient Safety Technologies, Inc.
SurgiCount Safety-Sponge System



Berchtold Holding AG
Integrated MRI Suite, including Stryker Navigation

Small Bone Innovations, Inc. (SBi)
STAR Total Ankle Replacement System

stryker®

ACCELERATING GLOBAL GROWTH



- Continue strong United States performance
- Grow in Europe behind new model
- Recover in Japan
- Continue momentum in emerging markets
  - Focus in China, India & Latin America
  - Expand Trauson

stryker®

FOCUSED ON INNOVATION

- Demonstrating commitment to internal innovation
- Driving innovation with products and services
- Focusing on improved outcomes and delivering greater cost savings/efficiencies

+10%
3 Year CAGR*
R&D

* 3 year CAGR is for periods 2012 - 2014

stryker®

OPERATING LEVERAGE INITIATIVES

- Amplify the Global Quality & Operations cost reduction program
- Reduce inventories through product rationalization
- Drive SG&A savings via shared services
- Simplify and rationalize our information technology footprint

stryker®

CONTINUED STRENGTH THROUGH M&A



- Targeting core and key adjacent markets
- Accelerating our top line, driving innovation

stryker®

CONSISTENTLY STRONG BALANCE SHEET

- Strong balance sheet with $5 billion of cash at 12/31/14 and > $1 billion of net cash*
- Consistent capital allocation strategy
  - Acquisitions to drive sales growth and innovation
  - Dividends
  - Share repurchases

* Net Cash = Total Cash & Short-Term Investments less Debt

stryker®

2014 STOCK PRICE: STRYKER vs. S&P 500



stryker®

SUMMARY

We are well positioned for the future as we continue to:

- Drive organic growth at the high-end of MedTech
- Deliver operational leverage
- Maintain a healthy balance sheet and cash flow generation
- Introduce a steady flow of innovation through R&D and acquisitions

Voting Results

Q & A

stryker®